NCT01265394

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 218 (actual)
• Sponsor: GE Healthcare · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Amyloid is an abnormal chemical found in the brain of patients with Alzheimer's Disease (AD). The study drug helps produce pictures of amyloid in the brain. The purpose of this study is to determine how well the study drug performs in young healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[18F] Flutemetamol	Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-03-01
• Completion: 2011-04-01
• First posted: 2010-12-23
• Last updated: 2013-07-02
• Results posted: 2013-06-21

Locations

1 site across 1 country: United States